<table cellpadding="4" id="b3b9f1c1-c2f7-4abb-be7d-a1862c8854c8" width="500" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<thead>
<tr stylecode="toprule">
<td align="center" colspan="2">
<content stylecode="bold">Table 4 Drugs Tested in <content stylecode="italics">In Vitro</content> Binding or <content stylecode="italics">In Vivo</content> Drug Interaction Testing or With Post-Marketing Reports</content>
</td>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="2">
<sup>a</sup> Should be administered at least 4 hours prior to WELCHOL</td>
</tr>
<tr>
<td align="left" colspan="2">
<sup>b</sup> No significant alteration of warfarin drug levels with warfarin and WELCHOL coadministration in an <content stylecode="italics">in vivo</content> study which did not evaluate warfarin pharmacodynamics (INR). <content stylecode="italics">[See Post-marketing Experience <linkhtml href="#E8D51915-C0CF-49D8-889F-A8DADBABC6DA">(6.2)</linkhtml>]</content>
</td>
</tr>
<tr>
<td align="left" colspan="2">
<sup>c</sup> Cyclosporine levels should be monitored and, based on theoretical grounds, cyclosporine should be administered at least 4 hours prior to WELCHOL.</td>
</tr>
<tr>
<td align="left" colspan="2">
<sup>d</sup>  Patients receiving concomitant metformin ER and colesevelam should be monitored for clinical response as is usual for the use of anti-diabetes drugs.</td>
</tr>
</tfoot>
<tbody>
<tr>
<td stylecode="botrule lrule rrule">Drugs with a known interaction with colesevelam:  Decrease in exposure of coadministered drug</td>
<td stylecode="botrule rrule">cyclosporine<sup>c</sup>, glimepiride<sup>a</sup>, glipizide<sup>a</sup>, glyburide<sup>a</sup>, levothyroxine<sup>a</sup>, olmesartan medoxomil<sup>a</sup>, and oral contraceptives containing ethinyl estradiol and norethindrone<sup>a</sup>
</td>
</tr>
<tr>
<td stylecode="botrule lrule rrule">Drugs with a known interaction with colesevelam:  Increase in exposure of coadministered drug</td>
<td stylecode="botrule rrule">metformin extended release (ER)<sup>d</sup>
</td>
</tr>
<tr>
<td stylecode="botrule lrule rrule">Drug(s) with postmarketing reports consistent with potential drug-drug interactions when coadministered with WELCHOL</td>
<td stylecode="botrule rrule">phenytoin<sup>a</sup>, warfarin<sup>b</sup>
</td>
</tr>
<tr>
<td stylecode="botrule lrule rrule">Drugs that do not interact with colesevelam based on <content stylecode="italics">in vitro</content> or <content stylecode="italics">in vivo</content> testing </td>
<td stylecode="botrule rrule">aspirin, atenolol, cephalexin, ciprofloxacin, digoxin, enalapril, fenofibrate, lovastatin, metformin, metoprolol, phenytoin<sup>a</sup>, pioglitazone, rosiglitazone, quinidine, repaglinide, sitagliptin, valproic acid, verapamil, warfarin<sup>b</sup>
</td>
</tr>
</tbody>
</table>